Dyslipidemia

•	Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia Pruski M, Krysiak R, Okopien B Diabetes Care. 2009;32(8):1421-1424
•	Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes Gatti A, Maranghi M, Bacci S, et al Diabetes Care. 2009;32(8):1550-1552
•	The pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia Pruski M, Krysiak R, Okopien B Diabetes Care. 2009 May 12. [Epub ahead of print]
•	Elevated triglycerides correlate with progression of diabetic neuropathy Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL Diabetes. 2009;58(7):1634-1640
•	Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW Ann Intern Med. 2009;150(11):741-751
•	Poor glycemic control is an independent risk factor for low HDL-C in patients with type 2 diabetes Gatti A, Maranghi M, Bacci S, et al Diabetes Care. 2009 Jun 1. [Epub ahead of print]
•	Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M Diabetes. 2009;58(5):1212-1221
•	Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the US Michos ED, Blumenthal RS J Am Coll Cardiol. 2009;53(11):931-935
•	Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study Raymond NT, Varadhan L, Reynold DR, et al, for the UK Asian Diabetes Study Retinopathy Study Group Diabetes Care. 2009;32(3):410-415
•	Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al J Diabetes and Its Complications. 2008 Oct 10. [Epub ahead of print]
•	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient Fruchart JC, Sacks FM, Hermans MP, et al, for the Residual Risk Reduction Initiative (R3I) Diab Vasc Dis Res. 2008;5(4):319-35
•	Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial Howard BV, Roman MJ, Devereux RB, et al JAMA. 2008;299(14):1678-1689
•	Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A, Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J JAMA. (14):1678-89
•	Reinventing type 2 diabetes: pathogenesis, treatment, and prevention Unger RH. JAMA. 299(10):1185-7
•	Effects of torcetrapib in patients at high risk for coronary events Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators N Engl J Med. 357(21):2109-22
•	Long-term follow-up of the West of Scotland Coronary Prevention Study. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group. N Engl J Med. 357(15):1477-86
•	Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. ACC Abstracts of the 48th Scientific Session. 298(3):309-16
•	Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G Diabetes Care. 30(8):2119-21
•	Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S. Circulation. 2007 May 8;115(18):2398-409
•	Combining population health and baseline risk strategy by determining an age cutoff for initiating statins in patients with diabetes: a population-based study Siyambalapitiya S, Bulugahapitiya U, Sithole J, Song S, Fernando DJ, Idris I. ACC Abstracts of the 48th Scientific Session. 2007 Aug;30(8):2025-9.
•	Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. JAMA. JAMA. 2007 Jul 18;298(3):336-8.
•	Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH Diabetes Care. 30(10):2458-64
•	Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy Yu D, Murdoch SJ, Parikh SJ, et al Diab Vasc Dis Res. 2006;3:189-196
•	Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C Atherosclerosis. 2006;189:369-374
•	Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Matikainen N, Manttari S, Schweizer A, et al Diabetologia. 2006;49:2049-2057
•	Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey Resnick HE, Foster GL, Bardsley J, Ratner RE Diabetes Care. 2006;29:531-537
•	Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Barzilay JI, Davis BR, Cutler JA, et al, for the ALLHAT Collaborative Research Group Arch Intern Med. 2006;166:2191-2201
•	Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies Hayashi T, Hirano T, Yamamoto T, Ito Y, Adachi M Metabolism. 2006;55:879-884
•	The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE Trial Sub-study Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J Curr Med Res Opin. 2006;22:343-350
•	Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes? Shepherd J Atheroscler Suppl. 2005;6:15-19
•	What is the most effective strategy for managing diabetic dyslipidaemia? Reasner CA Atheroscler Suppl. 2005;6:21-27
•	A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Goldberg RB, Kendall DM, Deeg MA, et al Diabetes Care. 2005;28:1547-1554
•	Pathophysiology of dyslipidaemia in the metabolic syndrome Kolovou GD, Anagnostopoulou KK, Cokkinos DV Postgrad Med J. 2005;81:358-366
•	Addressing the Global Cardiovascular Risk of Hypertension Dyslipidemia Diabetes Mellitus and the Metabolic Syndrome... Bestermann W, Houston MC, Basile J, et al Am J Med Sci. 2005;329:292-305
•	Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes van Wijk JP, de Koning EJ, Castro CM, Rabelink TJ Diabetes Care. 2005;28:844-849
•	Adherence to Statin Therapy and LDL Cholesterol Goal Attainment by Patients With Diabetes and Dyslipidemia Parris ES, Lawrence DB, Mohn LA, Long LB Diabetes Care. 2005;28:595-599
•	Impact of Adjunctive Thiazolidinedione Therapy on Blood Lipid Levels and Glycemic Control in Patients With Type 2 Diabetes Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H Curr Med Res Opin. 2004;20:215-223
•	The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes Temelkova-Kurktschiev T, Hanefeld M. Exp Clin Endocrinol Diabetes.. 2004:112:75-79
•	Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless PD Diabetes Care. 2004;27:41-46
•	Thiazolidinediones and Blood Lipids in Type 2 Diabetes van Wijk JPH, de Koning EJP, Martens EP, Rabelink TJ Arterioscler Thromb Vasc Biol.. 2003;23:1744-1749
•	Specialist Nurse-Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes (SPLINT) New JP, Mason JM, Freemantle N, et al Diabetes Care. 2003;26:2250-2255
•	Management of Dyslipidemia in Children and Adolescents With Diabetes American Diabetes Association Diabetes Care. 2003;26:2194-2197
•	Lipid Testing Among Patients With Diabetes Who Receive Diabetes Care From Primary Care Physicians Massing MW, Henley NS, Carter-Edwards L, Schenck AP, Simpson RJ Diabetes Care. 2003;26:1369-1373
•	Low Adiponectin Levels in Adolescent Obesity: A Marker of Increased Intramyocellular Lipid Accumulation Weiss R, Dufour S, Groszmann A, et al J Clin Endocrinol Metab. 2003;88:2014-2018
•	Disparities in Use of Lipid-Lowering Medications Among People With Type 2 Diabetes Mellitus Safford M, Eaton L, Hawley G, Brimacombe M, Rajan M, Li H, Pogach L Arch Intern Med. 2003;163:922-928
•	Diabetes Contributes to Cholesterol Metabolism Regardless of Obesity Simonen PP, Gylling HK, Miettinen TA. Diabetes Care. 2002;25:1511-1515.
•	Pharmacologic Lipid Management in Diabetic Patients With History of Coronary Artery Disease Not Adequate, Study Finds
•	Ratio of Triglycerides to HDL Cholesterol Is an Indicator of LDL Particle Size in Patients With Type 2 Diabetes and Normal HDL Cholesterol Levels Boizel R, Benhamou PY, Lardy B, et al. Diabetes Care. 2000;23:1679-1685
•	Weight Reduction in Type 2 Diabetic Subjects Results in a Redistribution of Apo A-I in HDL Subclasses to a Pattern that is Similar to that in Lean Subjects
•	Triglycerides, Apo C3 and Lp B:C3 and Cardiovascular Risk in Type 2 Diabetes
•	VLDL Subfractions in Type 2 Diabetes McEneny J, O"Kane MJ, Moles KW, et al. Diabetologia. 2000;43:485-493
•	HMG-CoA Reductase Inhibitors Increase BMD in Type 2 Diabetes Mellitus Patients
•	Fasting Remnant Lipoprotein Cholesterol and Triglyceride Concentrations Are Elevated in Nondiabetic, Insulin-Resistant, Female Volunteers
•	Influence of Low Density Lipoprotein (LDL) Subfraction Profile and LDL Oxidation on Endothelium-Dependent and Independent Vasodilation in Patients With Type 2 Diabetes
•	Cardiovascular Disease in the Diabetic Woman
•	Apolipoprotein(B) Identifies Dyslipidemic Phenotypes Associated With Cardiovascular Risk in Normocholesterolemic Type 2 Diabetic Patients
•	Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.
•	Impaired Endothelium-Dependent Vasodilation in Men With Type 2 Diabetes May Reflect an Abnormality of LDL Quality, Not Quantity McNeill KL, Fontana L, Russell-Jones DL, et al. JAMA. 2000;35:1622-1627

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.

Disclaimer Statement - Privacy Statement